Mithra Reports Full Year 2020 Financial Results

  • Strengthening of the financial resources and balance sheet structure via various funding transactions for an amount of EUR 260 million, diversifying the sources of financing
  • Record cash position of EUR 138.7 million allowing the continuation of our Business Development strategy for Donesta® and R&D projects beyond Women’s Health, notably in Covid-19 treatment
  • Licensing milestones from backlog contracts signed for Estelle® amount to more than EUR 450 million, with more than EUR 300 million cash to still be collected
  • First marketing authorization (MA) obtained for lead asset Estelle® in Canada, with other MA expected in Europe and the United States in the first half of 2021

 Liege, Belgium, 09 March 2021 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its financial results for the year ended 31 December 2020, prepared in accordance with IFRS.